| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
67 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-163 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Opthea Limited is a biotechnology company based in Australia that specializes in the development of novel therapies for the treatment of eye diseases. The company focuses on developing drugs that target the growth factors responsible for the formation of abnormal blood vessels and inflammation that can lead to vision loss.
Opthea's lead product candidate, OPT-302, is a novel biologic therapy designed to provide a more effective treatment for retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). OPT-302 works by inhibiting the activity of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which play a key role in the development of abnormal blood vessels and inflammation in the eye.
The company's goal is to improve the standard of care for patients suffering from vision-threatening eye diseases through the development of safe and effective therapies. With a strong focus on research and development, Opthea continues to advance its pipeline of innovative treatments, leveraging its expertise in biologics and ophthalmology.
Opthea has established partnerships with pharmaceutical companies and academic institutions to support the development and commercialization of its therapeutic candidates. The company is committed to bringing its innovative therapies to market and making a positive impact on patients' lives.
Company Address: C/- Prime Company Compliance Melbourne 3000
Company Phone Number: 9826 0399 Stock Exchange / Ticker: NASDAQ OPT
|
0.000%
